A Madison company that is developing a prostate cancer vaccine closed on an $8 million financing round led by Venture Investors. Madison Vaccines, Inc., is working on two vaccines, including one that is currently in Phase 2 clinical trials, according to a report in the Wisconsin State Journal. Other investors include WARF, Venture Management, and the State of Wisconsin Investment Board.
Madison Vaccines closes on financing round
Get Our Email Newsletter
The companies, people and issues shaping business in Madison and the Capital Region.
